Point72 Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

Point72 Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$455K	Buy	+43,627	New	+$323K	﹤0.01%	3214
2026 Q1	–	Sell	-33,871	Closed	-$244K	–	4381
2025 Q4	$244K	Buy	+33,871	New	+$274K	﹤0.01%	3560
2020 Q4	–	Sell	-13,333	Closed	-$992K	–	1100
2020 Q3	$992K	Sell	13,333 -20,000	-60%	-$1.53M	0.01%	779
2020 Q2	$2.84M	Buy	33,333 +4,549	+16%	+$412K	0.02%	552
2020 Q1	$2.08M	Buy	+28,784	New	+$2.78M	0.02%	500
2018 Q1	–	Sell	-3,338	Closed	-$982K	–	1094
2017 Q4	$982K	Buy	+3,338	New	+$1.46M	﹤0.01%	804
2017 Q3	–	Sell	-3,995	Closed	-$2.38M	–	1030
2017 Q2	$2.38M	Buy	+3,995	New	+$1.76M	0.01%	621

Other funds holding RNAC

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management's RNAC Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 43,627 shares worth $455K. The stake represents ﹤0.01% of the portfolio and ranks #3214 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in RNAC as recently as Q4 2025.

Point72 Asset Management first reported a position in RNAC in Q2 2017 and has held it in 7 quarters since. The position peaked at $2.84M in Q2 2020. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

Point72 Asset Management held 43,627 shares of Cartesian Therapeutics worth $455K as of Q2 2026.
Cartesian Therapeutics was a new Point72 Asset Management position in Q2 2026.
Cartesian Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #3214 holding.
Point72 Asset Management first reported a position in Cartesian Therapeutics in Q2 2017 and has held it in 7 quarters since.
Point72 Asset Management's Cartesian Therapeutics position peaked at $2.84M in Q2 2020.
95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.